Meet the expert...

Dr Andrew Bellinger, M.D., PH.D.

Chief Scientific Officer at Verve Therapeutics

Dr. Andrew Bellinger is the chief scientific and medical officer of Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Dr. Bellinger is board-certified in cardiovascular medicine and internal medicine and previously practiced cardiology at Brigham and Women’s Hospital. Prior to joining Verve, Dr. Bellinger co-founded and served as chief scientific officer of Lyndra Therapeutics. Dr. Bellinger completed his training in internal medicine at the University of California, San Francisco and his training in cardiology at Brigham and Women’s Hospital. Dr. Bellinger holds an M.D., a Ph.D., and an MPhil from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University.
Your cart